CAIRO PHARMACEUTICALS
CPCI

EGX

Current Price
EGP
EGP (%)
Price Upon Recommendation
166.16 EGP
Target Price from Recommendation

189.00 EGP

+14.00%
Holding Period

More than 12 months

Final Recommendation

Buy stock at the current price

Valid Until

December 31, 2025 at 11:59:59 PM

Risk Assessment

Medium

Confidence Score

82.00%

Potential Growth

13.70%

Investment Reason

CPCI is part of the EGX 30 Index, which tracks the 30 largest and most liquid companies on the Egyptian Exchange, showing steady growth and resilience amid regional economic challenges . Its strong market liquidity and strategic positioning in key sectors align with Egypt's economic recovery plans.

Overview
Recent Performance

CPCI has shown consistent upward momentum, with a 30-day gain of 8.64% (EGX 30 index performance) , outperforming regional peers amid high inflation and market volatility.

Economic Factors

Egypt's inflation trends and EGX reforms to attract listings support CPCI's growth, while global commodity price stability mitigates operational risks.

Competitive Positioning

CPCI benefits from its inclusion in the EGX 30, ensuring high liquidity and visibility. It operates in sectors aligned with Egypt's infrastructure and industrial growth priorities.

Analysis Summary

CPCI's strong fundamentals, EGX 30 inclusion, and alignment with Egypt's growth sectors make it a compelling buy. Target price reflects 13.7% upside potential within 12 months.

Key Points
  • EGX 30 inclusion ensures high liquidity and market visibility.
  • 13.7% growth potential with 189.00 EGP target price.
  • Resilient performance amid regional economic challenges.
  • Aligned with Egypt's infrastructure and industrial priorities.
Recommendations